- Home
- TSHA vs GPCR Comparison
TSHA vs GPCR Comparison
Compare TSHA & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- GPCR
- Stock Information
- Founded
- TSHA 2019
- GPCR 2016
- Country
- TSHA United States
- GPCR United States
- Employees
- TSHA N/A
- GPCR N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- GPCR
- Sector
- TSHA Health Care
- GPCR
- Exchange
- TSHA Nasdaq
- GPCR Nasdaq
- Market Cap
- TSHA 1.4B
- GPCR 1.2B
- IPO Year
- TSHA 2020
- GPCR 2023
- Fundamental
- Price
- TSHA $3.84
- GPCR $33.00
- Analyst Decision
- TSHA Strong Buy
- GPCR Strong Buy
- Analyst Count
- TSHA 9
- GPCR 8
- Target Price
- TSHA $10.22
- GPCR $69.57
- AVG Volume (30 Days)
- TSHA 4.1M
- GPCR 838.7K
- Earning Date
- TSHA 11-04-2025
- GPCR 11-13-2025
- Dividend Yield
- TSHA N/A
- GPCR N/A
- EPS Growth
- TSHA N/A
- GPCR N/A
- EPS
- TSHA N/A
- GPCR N/A
- Revenue
- TSHA $6,310,000.00
- GPCR N/A
- Revenue This Year
- TSHA N/A
- GPCR N/A
- Revenue Next Year
- TSHA N/A
- GPCR N/A
- P/E Ratio
- TSHA N/A
- GPCR N/A
- Revenue Growth
- TSHA N/A
- GPCR N/A
- 52 Week Low
- TSHA $1.05
- GPCR $13.22
- 52 Week High
- TSHA $5.51
- GPCR $40.06
- Technical
- Relative Strength Index (RSI)
- TSHA 37.78
- GPCR 64.72
- Support Level
- TSHA $3.89
- GPCR $31.50
- Resistance Level
- TSHA $4.55
- GPCR $34.50
- Average True Range (ATR)
- TSHA 0.39
- GPCR 1.72
- MACD
- TSHA -0.19
- GPCR 0.29
- Stochastic Oscillator
- TSHA 8.99
- GPCR 85.30
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.